1. Anderson R et al. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Sym Manage. 2001; 21:397-406
  2. Bruera E, Pereira J, Watanabe S et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78(4):852-57
  3. Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: Opioid switching to improve analgesia or reduce side effects. A systematic review. Palliative Medicine 2011;25:494-503
  4. Faculty of Pain Medicine. Principles regarding the use of opioid analgesics in patients with chronic non-cancer pain. 2015
  5. Fine PG, Portenoy RK. Establishing "Best Practices" for Opioid Rotation: Conclusions of an Expert Panel. J Pain Sym Manage 2009;38:418-425
  6. Galvez R, Schafer M, Hans G, Falke D, Steigerwald I. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Advances in Therapy 2013; 30(3): 229-259.
  7. Glare PA, Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol. 1993;11(5):973-8
  8. Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain". Cancer. 1997;79(7):1428-37
  9. Houde R, Wallenstein S, Beaver W. Evaluation of analgesics in patients with cancer pain. Clin Pharm. 1966;1:59–97
  10. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990;47(5):639-46
  11. Kalso E, Vainio A et al. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol. 1990;67(4):322-28
  12. Knotkova H, Fine PG, Portenoy RK. Opioid Rotation: The science and the limitations of the equianalgesic dose table. J Pain Sym Manage 2009;38:426-439
  13. Lawal, O., et al. Assessment of a systematic framework to determine the equianalgesic conversion ratio between opioids: Determining the conversion ratio between tapentadol and morphine. Pain Medicine (United States) 2018; 19 (4): 869.
  14. Mahler DL, Forrest WH. Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology 1975;42(5):602–607
  15. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliative Medicine 2011;25(5):504-515
  16. Mercadante S, Porzio G, Aielli F, Adile C, Verna L, Ficorella C, Giarratano A, Casuccio A. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Current Medical Research and Opinion 2013; 29:6, 661-666
  17. Pereira J, Lawlor P, Vigano A et al. Equianalgesic dose ratios of opioids: a critical review and proposals for long-term dosing. J Pain Sym Manage 2001;22:672-687
  18. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27(2):225-37
  19. Skaer TL. Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain. J Pain Research 2014;7:495-503
  20. The Royal Australasian College of Physicians. Prescription Opioid Policy: Improving management of chronic non-malignant pain and prevention of problems associated with prescription opioid use. Sydney 2008